WO2023031770 - TREATMENTS FOR ATOPIC DERMATITIS
National phase entry:
Publication Number
WO/2023/031770
Publication Date
09.03.2023
International Application No.
PCT/IB2022/058081
International Filing Date
29.08.2022
Title **
[English]
TREATMENTS FOR ATOPIC DERMATITIS
[French]
TRAITEMENTS CONTRE LA DERMATITE ATOPIQUE
Applicants **
GALDERMA HOLDING SA
Zählerweg 10
6300 Zug, CH
CHUGAI SEIYAKU KABUSHIKI KAISHA
5-1, Ukima 5-Chome, Kita-Ku
Tokyo, Tokyo 115-8543, JP
Inventors
KRISHNASWAMY, Jayendra Kumar
Chemin du Chateau-Sec 29
1009 Pully, CH
PIKETTY, Christophe
18 Bld Paul Baudin
45200 Montargis, FR
Priority Data
63/238,643
30.08.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 3147 | |
| EPO | Filing, Examination | 20188 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 16010 |
Total: 40507 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
., nemolizumab).[French]
L'invention concerne également des biomarqueurs de la DA et des procédés de modification ou d'amélioration de ces biomarqueurs par l'intermédiaire de traitements avec un anticorps qui se lie à IL-31RA (par exemple, némolizumab).